A drug manufacturer asked the Supreme Court on Saturday to immediately pause a lower-court order reinstating a requirement that a commonly used abortion pill, which has often been accessed through the mail, can only be picked up in person.
Danco Laboratories filed the emergency appeal after the U.S. Court of Appeals for the 5th Circuit in New Orleans issued a ruling Friday making it harder for women to access the abortion pill, mifepristone. It’s unclear when the Supreme Court might rule on the emergency application.
The ruling came in a Louisiana lawsuit against the Food and Drug Administration, which had previously allowed patients to access pills through telehealth and the mail. The rise of the use of such drugs has troubled antiabortion advocates.
“It bears emphasis how unprecedented the Fifth Circuit’s order is,” Danco wrote in its application to the Supreme Court. “Never before has a federal court purported to immediately enjoin a several years’ old drug approval; restrict a distribution system for that drug that manufacturers, providers, patients, and pharmacies have all been using for years; or reinstate conditions that FDA determined do not meet the mandatory statutory criteria.”
After the Supreme Court eliminated Roe v. Wade in 2022, legal experts and abortion advocates forged a new path to preserve access, even in states with severe restrictions.
“We’re now going to see, I think in a way we haven’t before, what the nation will look like when abortion bans are actually in effect,” said Mary Ziegler, an expert on abortion law and a professor at University of California at Davis School of Law, said before Saturday’s appeal.
‘Shield laws’
In eight Democratic-led states where the procedure remained legal, they worked to pass “shield laws” — measures that allow providers to remotely prescribe and mail the drugs to women regardless of where they live. Shield laws, which explicitly protect providers from out-of-state prosecution, have kept abortion pills flowing into all 50 states.
As the pill-mailing network flourished, so did the legal challenges against it. Anti-abortion advocates grew increasingly frustrated that women living under abortion bans could still legally end their pregnancies post-Roe. They began waging novel legal battles against online pill-mailing services and individual abortion providers.
“The regulation creates an effective way for an out-of-state prescriber to place the drug in the hands of Louisianans in defiance of Louisiana law,” Judge Kyle Duncan, who was appointed by President Donald Trump, wrote in Friday’s ruling.
A half dozen Republican-led states sued the FDA over the requirements to dispense mifepristone. Antiabortion strategists have helped draft first-of-their-kind laws in conservative states like Texas to further curb access to abortion pills and punish those who help distribute them.
Frustrated with a lack of federal action against medicated abortions, Louisiana Attorney General Liz Murrill sued the FDA last month, saying its regulations undermined the state’s ban on abortions at all stages of pregnancy.
Ms. Murrill, a Republican, celebrated the ruling as a “victory for life” while other anti-abortion advocates cheered the reversal of rules finalized under President Joe Biden that ended a longstanding requirement that the pills be obtained at an in-person doctor’s visit.
Representatives for the FDA and the U.S. Department of Justice did not immediately respond to requests for comment.
Pressure on Trump
The anti-abortion movement has also repeatedly pressured the Trump administration and the FDA to rein in abortion drug access. Still, those myriad efforts had done little to keep women from accessing abortion pills — until Friday’s ruling. Legal scholars have expected the abortion pill issue to again appear before the Supreme Court for years.
The FDA approved mifepristone in 2000, and major medical organizations say there is “robust evidence” collected over more than two decades showing the pill is safe and effective.
Mifepristone is used in conjunction with another drug, misoprostol. The agency has imposed a safety protocol over the use of mifepristone and some of those restrictions have been eased over the years — including eliminating the requirement for the drug to be dispensed in person. Legal experts have previously expressed concern about rulings to restrict the abortion pill, worrying it could politicize the regulatory environment and prompt further lawsuits over controversial treatments.
Abortion providers have braced for rulings that could curtail access to the drug before. They’ve weighed what to do if that were the case, and had discussed potentially switching to a misoprostol-only regimen. Misoprostol can be used on its own but is considered somewhat less effective and can cause longer discomfort and cramping.
Abortion policy could come into play in the midterms
The case could again make abortion a key issue in the midterm elections as Democrats aim to take back control of the U.S. House and Republicans fight to hold on to a narrow majority.
“This is going to be a pretty significant change in terms of how people experience abortion access, probably as significant as anything we’ve seen since Roe was overturned,” Ms. Ziegler said. “So another big question mark is going to be the extent to which voters feel that before they go to the polls, and the extent to which it becomes then an election issue.”
Ms. Ziegler said the case also “sort of puts the president in the position of having to get off the sidelines on this issue in a way we haven’t seen before.”
Recent electoral results suggest that voters seeking to maintain abortion access have the political momentum. Since Roe was overturned, abortion has been on the ballot directly in 17 states. Voters have sided with the abortion-rights side in 14 of those questions.
Abortion-rights supporter Fatima Goss Graves, president and CEO of the National Women’s Law Center, slammed the ruling as “deeply out of step with both the public and fact-based science.”
Trump received criticism after the ruling from some anti-abortion advocates who expressed frustration that he did not take action himself to block distribution of the pill.
The FDA under Trump approved another generic version of mifepristone last year, which peeved some allies of the Republican president.
“It’s shameful that the Trump administration’s inaction has forced pro-life states to take their battle to the federal courts,” said Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, who also applauded the ruling.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.